Ishikawa Asuka, Ohara Gen, Nakazawa Kensuke, Tamura Tomohiro, Sato Shinya, Kagohashi Katsunori, Kurishima Koichi, Ito Yoko, Satoh Hiroaki
Division of Pharmacy, Mito Kyodo General Hospital;
Division of Respiratory Medicine, Mito Medical Center, University of Tsukuba, Mito, Ibaraki 310-0015, Japan.
Mol Clin Oncol. 2013 Jan;1(1):65-68. doi: 10.3892/mco.2012.33. Epub 2012 Oct 2.
In lung cancer patients, chemotherapy-induced complications are considered to be distressing reactions even in the era of new antiemetics, such as aprepitant. The aim of this study was to evaluate the incidence of such complications. This prospective observational study was performed in our institution between 2011 and 2012. Certain complications including nausea, vomiting, appetite, stomatitis, constipation, diarrhea and dysesthesia, on days 1-7 were evaluated by pharmacists. The questionnaires and diaries of chemotherapy-induced complications were evaluated in the 31 patients included in the study. The majority of the enrolled patients were male (81%). Six (19%) patients were administered cis-diamminedichloroplatinum(II) (CDDP)-, 21 (69%) chemotherapy by carboplatin (CBDCA)- and 4 (13%) non-platinum regimen chemotherapies. Ten (32.3%) of the 31 patients exhibited nausea but only 3 (9.7%) of them experienced vomiting. On days 5-6, 23.8 and 9.5%, respectively, of patients treated with CDDP-regimens had nausea and vomiting. Three of the other most common complications were constipation, general fatigue and appetite loss. The incidence of these complications was 77.4, 71.0 and 67.7%, respectively. Even in the era of new antiemetics, CDDP-regimen chemotherapy-induced nausea and vomiting as well as constipation; general fatigue and appetite loss continue to be problems. A better appreciation of the incidence of these chemotherapy-related complications by medical oncologists and medical staff is essential for their adequate control.
在肺癌患者中，即使在新型止吐药（如阿瑞匹坦）出现的时代，化疗引起的并发症仍被视为令人痛苦的反应。本研究的目的是评估此类并发症的发生率。这项前瞻性观察研究于2011年至2012年在我们机构进行。药剂师对第1 - 7天出现的某些并发症进行评估，包括恶心、呕吐、食欲、口腔炎、便秘、腹泻和感觉异常。对纳入研究的31例患者的化疗引起并发症的问卷和日记进行了评估。大多数入选患者为男性（81%）。6例（19%）患者接受顺二氯二氨铂（CDDP）化疗，21例（69%）接受卡铂（CBDCA）化疗，4例（13%）接受非铂类方案化疗。31例患者中有10例（32.3%）出现恶心，但只有3例（9.7%）经历呕吐。在第5 - 6天，接受CDDP方案治疗的患者中分别有23.8%和9.5%出现恶心和呕吐。其他最常见的三种并发症是便秘、全身乏力和食欲减退。这些并发症的发生率分别为77.4%、71.0%和67.7%。即使在新型止吐药时代，CDDP方案化疗引起的恶心、呕吐以及便秘、全身乏力和食欲减退仍然是问题。肿瘤内科医生和医护人员更好地了解这些化疗相关并发症的发生率对于充分控制它们至关重要。
